A Study of Participants With Advanced Prostate Cancer in Canada

Official Title

A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada

Summary:

The purpose of this study is to document the course of advanced prostate cancer in Canada in terms of disease progression, real-world treatment, and patient management.

Trial Description

Primary Outcome:

• Time to Prostate Specific Antigen (PSA) Progression
• Time to Radiographic Evidence of Disease Progression
• Time to Skeletal-Related Events
• Time to Death
• Number of Participants with Different Primary Causes of Death
• Time to Progression from mCSPC to mCRPC in Participants with mCSPC
• Time from Biochemical Recurrence (BCR) to Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) and nmCRPC to mCRPC
• Number of Participants with PSA Testing from BCR to nmCRPC and nmCRPC to mCRPC, in Participants with mCRPC
• PSA Level at Start of Androgen Deprivation Therapy (ADT) in Participants with mCRPC
• PSA Doubling Time (PSAdt) at the Detection of Castration Resistance in Participants with mCRPC
• Time to Initiation of Subsequent Prostate Cancer Treatment
• Duration of Each Therapy
• Percentage of Participants Receiving Chemotherapy, Other Drug Treatments, or no Drug Treatment
• Time to Treatment Initiation
• Time to Dose Modification
• Number of Participants who Switch the Treatment
• Number of Participants who Discontinued the Treatment
• Most Common Sequences for Lines of Therapy in Participants with mCRPC
• Number of Participants Retreated with Docetaxel in Participants with mCRPC
• Percentage of Participant with Radiographic Imaging Modality
• Number of Days Hospitalized for Prostate Cancer or Treatment of Prostate Cancer
• Number of Visits to Emergency Department for Prostate Cancer or Treatment of Prostate Cancer
• Number of Outpatient Visits to Specialists Involved in Management of Prostate Cancer
• Charlson Comorbidity Index Score

View this trial on ClinicalTrials.gov